Skip to main content
Premium Trial:

Request an Annual Quote

LumaCyte: Paul Meister, Peter Buzy

LumaCyte, a developer of platforms for label-free, single-cell analytics, has appointed Paul Meister and Peter Buzy to its board of directors in connection with the completion of a Series A financing round for an undisclosed amount.

Meister is a partner in investment and advisory firm Novalis LifeSciences and a founder of private investment company Liberty Lane Partners. He previously was at Thermo Fisher Scientific and Fisher Scientific for more than 16 years, ultimately becoming chairman of the board. He also currently serves on the board of Ori Biotech, Quanterix, and other private life science companies, and is chairman of the board at Amneal Pharmaceuticals and Arbor Biotechnologies.

Buzy most recently served as chairman of Catalent's gene therapy division after joining the organization in 2019 as president of the gene therapy division. He was also president and CEO of Paragon Bioservices prior to its acquisition by Catalent.

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.